OmniAb shares surge 15.13% after-hours after licensing agreement with ArrowMark, Viking for antibody discovery programs.

OmniAb (NASDAQ: OABI) rose 15.13% in after-hours trading following the announcement of a technology license and services agreement with ArrowMark Partners and Mabtrx Biosciences. Under the deal, OmniAb will receive revenue for services, potential equity, and royalties for antibody discovery programs targeting Mabtrx’s defined needs. The partnership leverages OmniAb’s transgenic chicken-based platform to develop next-generation therapeutics, aligning with its business model of generating income through structured agreements. ArrowMark and Viking Global, key stakeholders in Mabtrx, are noted for their expertise in biotech investments, enhancing the strategic value of the collaboration. The agreement underscores OmniAb’s ability to monetize its technology through diversified revenue streams, including upfront fees, milestones, and future royalties, which likely drove the significant after-hours surge.